Scarica l'app Stockscreener
240.10
0.10%
-0.23
Pre-mercato:
240.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Resmed Inc Borsa (RMD) Ultime notizie
XY Capital Ltd Buys Shares of 36,769 ResMed Inc. $RMD - MarketBeat
Paralel Advisors LLC Buys Shares of 10,293 ResMed Inc. $RMD - MarketBeat
SGL Investment Advisors Inc. Purchases New Position in ResMed Inc. $RMD - MarketBeat
Wealthfront Advisers LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
13,498 Shares in ResMed Inc. $RMD Purchased by Fairtree Asset Management Pty Ltd - MarketBeat
Danske Bank A S Makes New Investment in ResMed Inc. $RMD - MarketBeat
Bank of New York Mellon Corp Takes $818.03 Million Position in ResMed Inc. $RMD - MarketBeat
Baird Mid Cap Growth Fund's ResMed Inc(RMD) Holding History - GuruFocus
ResMed Stock Bounces Back 4% This Week After Erasing Its Post Earnings Selloff - TIKR.com
ResMed (RMD) Today: Moves 0.67% Down to $228.44 in the Latest Session; Range Check: Price Remains Between $217.02 Support and $239.86 Resistance in the Current UpdateInvestment Factor - Vinanet
ResMed (RMD) Levels: Slides 0.10% to $229.76 on the Day; Current Setup: Traders Can Monitor the $218.27-$241.25 Range on the DayIV Spike - Vinanet
ResMed (NYSE:RMD) Faces Fresh Market Attention - Kalkine Media
ResMed stock climbs after earnings beat as analysts see valuation full - Ad-hoc-news.de
ResMed (NYSE:RMD) Upgraded to Hold at Rothschild & Co Redburn - MarketBeat
Rothschild & Co Redburn Initiates ResMed(RMD.US) With Hold Rating, Announces Target Price $230 - Moomoo
350,860 Shares in ResMed Inc. $RMD Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
BlackRock Inc. Makes New $2.40 Billion Investment in ResMed Inc. $RMD - MarketBeat
ResMed (RMD): Finishes 4.85% Up at $230.65 in the Current Update; Price Levels: Traders Can Monitor the $219.12-$242.18 Range at the CloseBreadth Thrust - Vinanet
Is It Too Late to Buy ResMed Inc (RMD) After 4.8% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Resmed Inc Stock (RMD) Moved Up by 3.43% on Aug 19: What Investors Need To Know - TradingKey
ResMed, Inc.: Target Price Consensus and Analysts Recommendations | RME | US7611521078 - marketscreener.com
Oxbow Advisors LLC Invests $5.57 Million in ResMed Inc. $RMD - MarketBeat
Rothschild Redburn initiates ResMed stock coverage with neutral rating By Investing.com - Investing.com South Africa
Rothschild Redburn initiates ResMed stock coverage with neutral rating - Investing.com
Deutsche Bank AG Takes Position in ResMed Inc. $RMD - MarketBeat
Resmed Announces Board Leadership Transition and Director Retirement - The Globe and Mail
ResMed stock slips as Q4 revenue rose 9% - AD HOC NEWS
Resmed board set to get new lead director - HME News
RESMED INC CDI COM USD0.004 (10CDI/1SHS) To Go Ex-Dividend On August 19th, 2026 With 0.066 USD Dividend Per Share - Moomoo
UNIVEST FINANCIAL Corp Acquires Shares of 12,846 ResMed Inc. $RMD - MarketBeat
Perigon Wealth Management LLC Invests $4.60 Million in ResMed Inc. $RMD - MarketBeat
5,358 Shares in ResMed Inc. $RMD Purchased by Flputnam Investment Management Co. - MarketBeat
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - Koreabizwire
ResMed (ASX:RMD) Faces Market Attention as Healthcare Technology Portfolio Continues to Evolve - Kalkine
ResMed (RMD) Announces Auditor Transition to PwC and Board Leade - GuruFocus
ResMed Replaces KPMG with PwC and Names Carol Burt as Lead Director - Kalkine
ResMed names Carol Burt as lead director, Ron Taylor to retire - Investing.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Resmed Names Carol Burt Lead Director as Ron Taylor Retires After 21 Years on Board - Quiver Quantitative
A lead director's 21-year Resmed tenure is set to end in November - Stock Titan
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Assessing a 10% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
ResMed names Carol Burt lead director as Ron Taylor steps down - Bitget
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
ResMed, Inc.: Financial Data Forecasts Estimates and Expectations | RME | US7611521078 - marketscreener.com
ResMed (ASX:RMD) Keeps Dividend Momentum Going: Keep It on Your Radar - Kalkine
ResMed to sell MatrixCare business for $490 million - Minichart
ResMed Inc. Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026 - Kalkine
ResMed Submits 2026 Fiscal Year-End 10-K Annual Report Detailing Financial and Operational Metrics - Kalkine Media
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234 - webull.com
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary - TradingView
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - simplywall.st
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more - Morningstar Australia
RESMED INC. : PIPER SANDLER CUTS TARGET PRICE TO $225 FROM $233 - webull.com
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
ResMed Could Expand Into More Sleep Disorder Treatments -- Interview - Moomoo
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
J.P. Morgan Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook - Yahoo Finance
0.07%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):